Optellum

Executive Summary

Optellum is a UK-based medical AI company founded in 2016, focused on revolutionizing early lung cancer diagnosis. Its AI-powered software platform integrates CT imaging and clinical data to characterize pulmonary nodules and stratify cancer risk, enabling clinicians to detect lung cancer at its most treatable stages. As a leader in the lung nodule AI space, Optellum addresses a critical unmet need: over 1.5 million pulmonary nodules are detected annually in the US alone, yet current diagnostic workflows suffer from high false-positive rates and delayed interventions. By providing decision-support tools that enhance accuracy and efficiency, Optellum aims to improve patient outcomes and reduce healthcare costs. The company has established a strong IP portfolio and is poised for commercial expansion pending regulatory clearances. The lung cancer diagnostics market is projected to exceed $20B by 2030, with AI-driven solutions capturing a growing share. Optellum's platform has demonstrated strong clinical validity through retrospective studies and is now targeting FDA clearance and CE marking for its flagship product. Key near-term milestones include completing a pivotal prospective study and securing strategic partnerships with major health systems. With increasing regulatory traction and a robust pipeline, Optellum is well-positioned to become a standard-of-care tool in lung nodule management. However, competition from established players and the need for reimbursement clarity remain key risks.

Upcoming Catalysts (preview)

• Q2 2026FDA 510(k) clearance for Optellum's AI lung nodule software70% success
• Q3 2026Publication of prospective clinical study results demonstrating improved diagnostic accuracy60% success
• Q4 2026Partnership with a major US health system for pilot deployment55% success